Pharmaxis (OTCMKTS:PXSLY – Get Free Report) and Northwest Biotherapeutics (OTCMKTS:NWBO – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, dividends, valuation and institutional ownership.
Earnings & Valuation
This table compares Pharmaxis and Northwest Biotherapeutics’ revenue, earnings per share and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Pharmaxis | $8.75 million | 3.03 | -$9.36 million | N/A | N/A |
Northwest Biotherapeutics | $1.93 million | 274.44 | -$62.60 million | ($0.07) | -6.17 |
Pharmaxis has higher revenue and earnings than Northwest Biotherapeutics.
Risk and Volatility
Analyst Ratings
This is a summary of current recommendations for Pharmaxis and Northwest Biotherapeutics, as provided by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Pharmaxis | 0 | 0 | 0 | 0 | N/A |
Northwest Biotherapeutics | 0 | 0 | 0 | 0 | N/A |
Insider and Institutional Ownership
0.0% of Northwest Biotherapeutics shares are owned by institutional investors. 8.7% of Northwest Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Profitability
This table compares Pharmaxis and Northwest Biotherapeutics’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Pharmaxis | N/A | N/A | N/A |
Northwest Biotherapeutics | -5,258.91% | N/A | -241.52% |
Summary
Pharmaxis beats Northwest Biotherapeutics on 5 of the 8 factors compared between the two stocks.
About Pharmaxis
Pharmaxis Ltd engages in the research, development, and commercialization of healthcare products for the treatment of fibrotic and inflammatory diseases worldwide. The company operates through two segments, Mannitol business, and New Drug Development. It offers Bronchitol, an inhaled dry powder for the treatment of cystic fibrosis; and Aridol, an airways inflammation test that is used to identify twitchy or hyper-responsive airways, as well as to assist in diagnosing and managing asthma. The company's product pipeline consists of amine oxidase inhibitors comprising semicarbazide-sensitive amine oxidase for diabetic retinopathy; selective lysyl oxidase like inhibitors targeting chronic fibrotic diseases, such as NASH, pulmonary fibrosis, kidney fibrosis, and cardiac fibrosis; and pan-lysyl oxidase inhibitors targeting severe fibrotic indications, which includes cancers and scarring. It is also developing Orbital, a dry powder inhaler to deliver high drug doses to lungs. Pharmaxis Ltd was founded in 1998 and is headquartered in Frenchs Forest, Australia.
About Northwest Biotherapeutics
Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.
Receive News & Ratings for Pharmaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharmaxis and related companies with MarketBeat.com's FREE daily email newsletter.